文献速递细胞病理与分子病理

肿瘤检测中偶然与次要胚系发现的实验室与临床意义

Laboratory and Clinical Implications of Incidental and Secondary Germline Findings During Tumor Testing.
PubMed 文献 · Arch Pathol Lab Med · 2022-01-01

美国病理学家学会工作组联合美国临床肿瘤学会、分子病理学协会和美国医学遗传学与基因组学学会,综述了肿瘤检测中偶然或次要胚系发现相关的临床与实验室问题。文章强调需区分预期偶然、非预期偶然与次要发现,并考虑是否检测正常组织,同时呼吁制定相关指南。

要点

  • 需区分预期偶然、非预期偶然与次要发现,并考虑是否检测正常组织。
  • 建议应涵盖变异报告范围、检测设计与验证、报销、成本、基础设施及能力验证。
  • 临床医生需考虑检测发现偶然或次要结果的可能性、预先咨询与知情同意。

核心结论

  • 肿瘤检测 panels 已成为临床癌症诊疗的支柱,需要针对偶然和次要发现的独特方面制定指南。
  • 本文强调相关临床与实验室考量,并呼吁制定推荐意见。

研究设计与样本

  • 美国病理学家学会工作组(含美国临床肿瘤学会、分子病理学协会和美国医学遗传学与基因组学学会代表)对制定偶然或次要发现指南时应考虑的事项进行综述。

主要发现

  • 检测建议应认知预期偶然、非预期偶然与次要发现之间的差异,以及是否也检测正常组织。
  • 稳健的建议除定义报告哪些变异外,还需考虑检测设计与验证、报销、成本、基础设施、对反射检测的影响及能力维持。
  • 照护提供者需考虑检测发现偶然或次要结果的可能性、预先咨询的建议、知情同意的需要、检测与咨询的时机,以及发现的确切意义可能不明确。

临床怎么用

  • 临床医生在肿瘤检测前应考虑偶然或次要胚系发现的可能性,并进行预先咨询和知情同意。
  • 实验室制定报告策略时需综合考量检测设计、验证、报销、成本及能力验证等多方面因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: Next-generation sequencing is a powerful clinical tool for cancer management but can produce incidental/secondary findings that require special consideration. OBJECTIVE.—: To discuss clinical and laboratory issues related to incidental or secondary germline findings in the clinical setting of tumor testing and inform future guidelines in this area. DESIGN.—: A College of American Pathologists workgroup including representation from the American Society of Clinical Oncology, the Association for Molecular Pathology, and the American College of Medical Genetics and Genomics created a review of items that should be considered when developing guidelines for incidental or secondary findings when performing clinical tumor testing. RESULTS.—: Testing recommendations should be cognizant of the differences among anticipated incidental, unanticipated incidental, and secondary findings, and whether normal tissue is also tested. In addition to defining which variants will be reported, robust recommendations must also take into account test design and validation, reimbursement, cost, infrastructure, impact on reflex testing, and maintenance of proficiency. Care providers need to consider the potential of a test to uncover incidental or secondary findings, the recommendation of upfront counseling, the need for consent, the timing of testing and counseling, and that the exact significance of a finding may not be clear. CONCLUSIONS.—: As clinical oncology testing panels have become a mainstay of clinical cancer care, guidelines addressing the unique aspects of incidental and secondary findings in oncology testing are needed. This paper highlights clinical and laboratory considerations with regard to incidental/secondary findings and is a clarion call to create recommendations.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Cushman-Vokoun A, Lauring J, Pfeifer J, et al. Laboratory and Clinical Implications of Incidental and Secondary Germline Findings During Tumor Testing. Arch Pathol Lab Med. 2022. PMID: 33769456. doi:10.5858/arpa.2020-0025-CP

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。